Clinical Trials

2,431 enrolled 13 charts

Colonic Neoplasms

NCT00310180 2026-03-18

TAILORx

10,273 enrolled 14 charts

Breast Neoplasms

NCT00569127 2026-03-18

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

427 enrolled 17 charts

EndocrineNET

Neuroendocrine Tumors

NCT00843882 2026-03-18

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Classical hematologyMyeloidOther hematologic neoplasm

247 enrolled 19 charts

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00980460 2026-03-18

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

236 enrolled 18 charts

PRETEXT I Hepatoblastoma

NCT01167712 2026-03-18

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT01272037 2026-03-18

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT01575548 2026-03-18

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

129 enrolled 11 charts

Carcinoma, Renal Cell

NCT01886872 2026-03-18

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

547 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02166463 2026-03-18

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

600 enrolled 14 charts 1 FDA

Lymphoid

Ann Arbor Stage IIB Hodgkin Lymphoma

NCT02193282 2026-03-18

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

390 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02466971 2026-03-18

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

450 enrolled 11 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT02468024 2026-03-18

STABLE-MATES

272 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

1,301 enrolled 16 charts

Dermatologic

Melanoma

NCT02598219 2026-03-18

SENTIRAD

262 enrolled

Carcinoma, Endometrioid

NCT02838420 2026-03-18

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

187 enrolled 14 charts

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT02845882 2026-03-18

LBL-2016 for Children or Adolescents in China

150 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02973789 2026-03-18

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Phase 3 Completed

291 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT02997228 2026-03-18

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

120 enrolled

Colorectal Neoplasms

NCT03233711 2026-03-18

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

344 enrolled

Anal Canal Carcinoma, Anus Neoplasms

NCT03244384 2026-03-18

AMBASSADOR

739 enrolled

Ureteral Neoplasms

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 1 FDA

Plasma cell

Smoldering Multiple Myeloma

NCT03375320 2026-03-18

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03663725 2026-03-18

StrateGlio

486 enrolled

CNS

Glioblastoma

NCT03701282 2026-03-18

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

720 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03775265 2026-03-18

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

475 enrolled

Urinary Bladder Neoplasms

NCT03793166 2026-03-18

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

1,175 enrolled

Carcinoma, Renal Cell, Lymphatic Metastasis

NCT03811002 2026-03-18

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

544 enrolled 29 charts

Lung Neoplasms

NCT03811015 2026-03-18

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

636 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT03871257 2026-03-18

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

165 enrolled

CNS

Neurofibromatosis 1

NCT03914625 2026-03-18

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

6,720 enrolled

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04031677 2026-03-18

STRASS2

250 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma

NCT04092283 2026-03-18

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

660 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04214067 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

164 enrolled

Sarcoma

Carcinosarcoma

NCT04214262 2026-03-18

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

480 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

453 enrolled

MyeloidOther hematologic neoplasm

Carcinoma, Non-Small-Cell Lung

NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Phase 3 Completed

199 enrolled 13 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05083169 2026-03-18

MajesTEC-3

587 enrolled 1 FDA

Plasma cell

Multiple Myeloma

NCT05092958 2026-03-18

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

654 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05100862 2026-03-18

MAHOGANY

780 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05256225 2026-03-18

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

360 enrolled

Neoplasms, Endometrial Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT05654623 2026-03-18

VERITAC-2

624 enrolled 17 charts

Breast Neoplasms

NCT05941741 2026-03-18

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06012435 2026-03-18

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

703 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT06058377 2026-03-18

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

3,680 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06151574 2026-03-18

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

416 enrolled

Lung Neoplasms

NCT06337318 2026-03-18

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

600 enrolled

Lymphoid

Classic Follicular Lymphoma

NCT06377852 2026-03-18

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

500 enrolled